Oncology

A new integrated test from NeoGenomics aims to slash diagnostic delays and streamline complex tumor profiling, promising faster, smarter cancer treatment.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A new report shows 40% of ANZ firms never assess skin cancer risk, despite 84% seeing it as a duty of care, exposing a massive legal and health liability.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

Hoag becomes the world's first Center of Excellence in Oncoplastic Surgery, a revolutionary approach merging cancer removal with cosmetic preservation.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

With its Phase 1 trial fully enrolled, Senti Bio’s logic-gated CAR-NK therapy shows deep, durable remissions, charting an expedited path for R/R AML.

Basketball icons partner with the Prostate Cancer Foundation in a new push for early screening, aiming to save lives and combat racial health disparities.

Radiation tech giant Mirion appoints three new executives, signaling a major strategic push into next-gen nuclear, advanced cancer care, and AI.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

Lantern's expanded cancer solution uses NCI-level expertise and community care to promise better outcomes and a significant return on investment for employers.

A new partnership with Uniphar will use managed access programs to provide the lymphoma therapy LYMPHIR to European patients with limited treatment options.

SOFIE Biosciences' FAPI-PRO trial begins, testing a novel radiotracer that could revolutionize the detection of one of the deadliest forms of cancer.

New 3D human tissue models show groundbreaking promise in predicting toxicity for advanced cancer therapies, heralding a major shift away from animal testing.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.

A newly identified molecule, HOXD13, both fuels melanoma growth and shields it from the immune system, paving the way for a novel combination therapy.